Medical Device Medicare Coverage: FDA Authorization Does Not Pay the Claim

Medical device Medicare coverage depends on the benefit category, the applicable coverage conditions and the care actually provided, even when the Food and Drug Administration has authorized the device for sale. A manufacturer can have marketing authorization and a billing code while the hospital still has to meet requirements about the patient, the treatment, the clinical team or the study. If you work in device sales, clinical support or reimbursement, the question is what the provider was told Medicare would pay for, and what it billed. A manufacturer’s reimbursement advice can reach the claim even when the hospital sends the bill.

How Does Reimbursement Work for Medical Devices?

Medicare usually pays for an implanted device through the procedure or hospital stay. The device’s purchase price, its billing code, coverage for its use and Medicare’s payment are different parts of the transaction. A sales presentation that compresses them into a promise of reimbursement leaves out the conditions that decide whether the claim pays.

The benefit category comes first. Medicare Part B covers items within defined categories, such as durable medical equipment. An item outside those categories, or excluded by law, cannot gain coverage merely by acquiring a code. Under the Social Security Act’s Medicare coverage provisions, the general coverage standard also asks whether care is reasonable and necessary for diagnosis or treatment.

A billing code does not establish Medicare payment: A9270 identifies a noncovered item or service and provides no Medicare payment.

Payment then determines where the money attaches. Hospital outpatient payment generally packages implants into the service payment. Inpatient payment includes their cost in the payment for the stay. Surgery centers also package implanted prosthetics and implanted durable medical equipment unless an exception applies. A device can appear on a claim without receiving a separate payment.

There are specific exceptions. An inpatient new technology add-on can supplement the hospital payment. Outpatient transitional pass-through provides temporary separate payment for a device category, after accounting for device cost already included in the procedure payment. Neither is simply Medicare paying the manufacturer’s invoice. For the reimbursement team, the useful distinction is between a product the hospital buys and the service Medicare pays the hospital to deliver.

What National and Local Coverage Determinations Require Beyond the Device

A national coverage determination sets Medicare coverage policy across the country. A local coverage determination comes from a Medicare Administrative Contractor and applies within its jurisdiction. These policies can make coverage depend on the patient’s condition, the treatment setting, the clinicians involved or participation in a study or registry.

Contractor coverage articles add coding and billing details. Local policies can differ between contractors and change over time.

A national device business must account for local coverage differences. A coverage representation that fits one contractor’s policy may leave out conditions another contractor applies. The useful comparison is the policy for the provider’s jurisdiction and service date, including the accompanying billing instructions. A generic statement about coverage in a state misses how the claims system is organized.

The transcatheter aortic valve replacement determination shows how detailed the national conditions can be. Under the version effective June 21, 2019, a hospital starting a TAVR program without prior TAVR experience must meet surgical-volume and staffing requirements, including at least 300 percutaneous coronary interventions per year. The determination also requires participation in a national audited registry that enrolls patients consecutively and accepts all manufactured devices. Selling an authorized valve to a hospital does not satisfy those conditions for it.

Patient circumstances can be just as decisive. The implantable pulmonary artery pressure sensor determination effective January 13, 2025 requires reliable connectivity for daily collection and submission of device data. Coverage here reaches beyond the implant and the operating room to whether the patient can transmit the measurements.

Coverage With Evidence Development Makes the Study Part of Coverage

Coverage with Evidence Development allows Medicare coverage under specified evidence-gathering conditions, such as a clinical study or registry. The Centers for Medicare & Medicaid Services says this generally expands access to technologies that would otherwise fall short of its reasonable-and-necessary standard. The Food and Drug Administration’s safety and effectiveness role remains separate.

For a hospital, the conditions attached to that access matter. The left atrial appendage closure determination requires Coverage with Evidence Development and documented shared decision making with an independent, non-interventional physician using an evidence-based decision tool. It treats the device as a second-line therapy to oral anticoagulants. The coverage question includes how the treatment decision was reached and recorded.

The registry requirements also carry substantive work. TAVR registry participation includes patient follow-up and outcome tracking. The left atrial appendage closure registry must track operator-specific complications. A registry file therefore connects the device program to the clinical activity Medicare required, rather than merely recording that a hospital owns the product.

The Centers for Medicare & Medicaid Services’ guidance released August 7, 2024 requires plans for public results and data sharing. Final results must be provided to the agency and submitted for publication or otherwise reported publicly within 12 months of the study’s primary completion date. Sponsors and investigators also commit to sharing data, methods, analytic code and analytical output with the agency or an approved third party.

Those requirements make evidence development part of the commercial arrangement. A sponsor’s coverage presentation, the study protocol and the site’s actual participation should describe the same arrangement. When they tell different stories, the question for a whistleblower case is which condition governed the paid claim and what the people making the reimbursement representation knew.

Investigational Device Studies Have Different Payment Rules

For an investigational device exemption study, Medicare coverage depends on the Food and Drug Administration’s device category and the applicable study-coverage requirements. The agency’s categorization letter and Medicare’s approval of study coverage perform different jobs.

Category A covers experimental devices whose device type still has unresolved basic safety and effectiveness questions. Medicare does not pay for the Category A device itself. It may cover routine care surrounding its use in an approved study.

Category B covers investigational devices where the device type is known to be capable of being safe and effective and the incremental risk is the main question. Medicare may cover the device as well as routine care in an approved study. Payment for the device cannot exceed what Medicare would have paid for a currently used, approved or cleared device serving the same medical purpose.

Study approval matters alongside the category. The Centers for Medicare & Medicaid Services publishes approved investigational device exemption studies. We compare the approval for the actual study, its protocol and the patient’s participation with what the hospital billed.

The surrounding services matter, too. For noncovered investigational devices, payment restrictions also extend to preparation, services necessary to use the device and necessary aftercare. Covered services treating a condition or complication caused by a noncovered device can still be paid. The permitted routine-care coverage in approved Category A studies is a separate part of this framework. For a hospital or study sponsor, a reimbursement promise that ignores those distinctions can misstate what Medicare will pay.

New Device Coverage Pathways Have Changed

Medicare Coverage of Innovative Technology, the MCIT pathway, was repealed in 2021 before it operated. A manufacturer’s promise of a route to Medicare coverage has to account for what happened to that route.

Transitional Coverage for Emerging Technologies took effect through a final notice published August 12, 2024. TCET was paused for new candidates on August 11, 2026. Describing it as an open route for a new device after that pause leaves out the change that matters to the sponsor.

Regulatory Alignment for Predictable and Immediate Device coverage, or RAPID, was proposed in the notice published August 11, 2026. The proposal would coordinate the Food and Drug Administration’s and Medicare’s evidence expectations and, with sufficient clinical evidence, aim to post a proposed national coverage determination on the day of marketing authorization.

Its proposed eligibility is also narrower than the broad promise of faster device coverage might suggest. It is limited to separately payable devices that could be billed to Medicare and are still at the investigational device exemption pre-submission stage. Devices already market-authorized or already being studied under an investigational device exemption fall outside that proposed route. So do devices whose payment is packaged into the procedure. For a manufacturer selling an implant, the payment model is therefore part of the pathway question from the beginning.

When Coverage Conditions Reach a False Claims Act Case

A coverage case connects what the provider represented to Medicare with the patient, procedure and conditions behind the bill. The national implantable cardioverter defibrillator investigation shows how that comparison can reach across hospitals.

In its October 2015 announcement, the Justice Department alleged that hospitals implanted defibrillators during prohibited waiting periods from 2003 through 2010. The department described the historical rule as generally requiring 40 days after a heart attack and 90 days after bypass surgery or angioplasty, with exceptions. The waiting periods were meant to spare patients an implant they might not need. The government alleged that hospitals billed Medicare for putting the devices in anyway.

The investigation used a panel of cardiologists and reviews of thousands of patient charts. A cardiac nurse and a health care reimbursement consultant had brought the whistleblower case. The device, the timing of treatment and the claim could be compared because those clinical events left records.

By its February 2016 announcement, the department reported settlements with more than 500 hospitals totaling more than $280 million. Those settlements turned on when the device went in.

Cape Cod Hospital shows the same issue in the process for deciding on treatment. In its May 2024 civil settlement, the hospital agreed to pay $24.3 million over the heart-team reviews behind its TAVR claims. It admitted failing to adhere to applicable Medicare requirements.

The allegations included missing independent examinations or documentation and sharing of clinical judgments. The requirements applied to claims from November 2015 through December 2022.

One campaign concerned waiting. The other concerned who evaluated the patient and how the decision was documented. Both put the clinical steps behind a hospital bill at the center of the coverage inquiry.

Manufacturer Reimbursement Advice Can Reach the Claim

Manufacturer reimbursement advice can supply the diagnosis or procedure code a customer later submits. Category III codes, which describe emerging technologies, make the distinction between the procedure and its billing particularly visible. THD America settled allegations in September 2024 that it encouraged additional or substitute codes to evade denials associated with the temporary procedure code. The alleged mechanism was the advice to bill something else.

The whistleblower complaint against Diopsys describes a different route through a reimbursement worksheet:

The whistleblower alleged that the worksheet used different names for glaucoma-related conditions to promote testing that Medicare would not cover for glaucoma. The allegation puts the sales tool, the diagnosis description and the expected payment in the same document. That is a concrete connection between a manufacturer’s representation and the customer’s billing decision.

What Evidence Is Needed to Prove Fraud?

We examine the device’s authorization, the coverage representation, the medical record and the bill with you. The connection that matters is what the manufacturer or provider knew and what Medicare was asked to pay.

A 2020 analysis in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, emphasizes whether a false statement had the practical effect of inducing wrongful payment. For device coverage, that directs attention to what a sales presentation or coding instruction caused the customer to submit.

Product identity may require records outside the claim. The Food and Drug Administration’s unique device identification system connects device labels with product information, while an ordinary hospital claim does not identify the implant by its unique device identifier. The product record and the patient chart can supply the connection the bill leaves out.

For a procedure involving FDA off-label use or a Category III code, we examine those actual coverage conditions rather than treating the label or code category as the whole payment decision. The reimbursement communication shows what the customer was told. The claim shows what Medicare was asked to pay.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The starting point for our work with you is the connection between what you saw inside the business and the claims it produced.

When the Coverage Pitch and the Claim Part Company

If you know a device’s reimbursement pitch left out the conditions the hospital had to meet, speak with our whistleblower experts about the pitch and the claims it produced. We work with you to build the case around the coverage rule, the clinical decisions and the money Medicare paid, and bring in medical device fraud whistleblower lawyers who understand hospital reimbursement. We stay beside you through the case.